Company profile: Primrose Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology research and development focused on creating treatments for polycystic kidney disease (PKD), a life-threatening genetic disorder affecting 600,000 Americans and 12.5 million people worldwide.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Primrose Therapeutics
Synageva BioPharma
HQ: United States
Website
- Description: Provider of novel, next generation and follow on protein therapeutics developed and commercialized using the proprietary Synageva Expression Platform (SEPTM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synageva BioPharma company profile →
Vidara Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceutical offerings, creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management; incorporated in 2003 and based in Dublin, Ireland.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vidara Therapeutics company profile →
Pharming
HQ: The Netherlands
Website
- Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharming company profile →
Longboard Pharmaceuticals
HQ: United States
Website
- Description: Provider of medicines with optimized pharmacology and pharmacokinetics for rare neurological diseases, with a proprietary pipeline including bexicaserin (LP352), an oral, centrally acting 5-HT2C receptor superagonist in development for treating seizures associated with Developmental and Epileptic Encephalopathies, and LP659, an oral S1P receptor modulator for rare neuroinflammatory conditions, plus Longboard Assist patient support services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Longboard Pharmaceuticals company profile →
uniQure
HQ: The Netherlands
Website
- Description: Provider of gene-based therapies focused on research and early development. Offerings include AMT-130 for Huntington’s disease, Etranacogene Dezaparvovec for severe or moderately severe Hemophilia B, AMT-260 for refractory temporal lobe epilepsy, AAV-miQURE targeting ALS C9orf72 transcripts, and the linQURE platform for multi-transcript targeting; a leader that developed the first and only EU-approved gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full uniQure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Primrose Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Primrose Therapeutics
2.2 - Growth funds investing in similar companies to Primrose Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Primrose Therapeutics
4.2 - Public trading comparable groups for Primrose Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →